Drugs Made In America Acquisition II Corp
DMII
68 hedge funds and large institutions have $438M invested in Drugs Made In America Acquisition II Corp in 2026 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 2 closing their positions.
850% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 2
356% more capital inflows, than outflows
Capital inflows: $117M | Capital outflows: $25.8M
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
33% more funds holding
Funds holding: 51 → 68 (+17)
14.45% more ownership
Funds ownership: 54.51% → 68.96% (+14%)
27% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$26.9M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$19.9M |
| 3 |
Karpus Investment Management
Pittsford,
New York
|
+$14.5M |
| 4 |
MCS
Mercuria Capital Strategies
Houston,
Texas
|
+$7.47M |
| 5 |
Wolverine Asset Management
Chicago,
Illinois
|
+$7.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Capital Management
Chicago,
Illinois
|
-$10M |
| 2 |
CL
CSS LLC
Chicago,
Illinois
|
-$6.93M |
| 3 |
Mizuho Securities USA
New York
|
-$1.97M |
| 4 |
Clear Street
New York
|
-$1.66M |
| 5 |
Cable Car Capital
San Francisco,
California
|
-$990K |
DMII Hedge Fund Activity: Q1 2026 in Review
68 of the 8,220 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition II Corp (DMII) for Q1 2026, worth a combined $438M — up 28% from $343M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new DMII positions and 2 closed out — a net gain of 17 holders — while 11 added to existing stakes and 15 trimmed.
The largest buyer was MMCAP International, opening a new position worth an estimated $26.9M. The largest seller was First Trust Capital Management, cutting an estimated $10M.
- 68 institutional investors held Drugs Made In America Acquisition II Corp (DMII) as of Q1 2026, up from 51 in Q4 2025.
- Funds reported $438M of Drugs Made In America Acquisition II Corp stock for Q1 2026, up 28% quarter-over-quarter.
- 19 funds opened new Drugs Made In America Acquisition II Corp positions in Q1 2026 and 2 closed out, a net change of +17 holders.
- The largest Drugs Made In America Acquisition II Corp buyer in Q1 2026 was MMCAP International, an estimated $26.9M added.
- The largest Drugs Made In America Acquisition II Corp seller in Q1 2026 was First Trust Capital Management, an estimated $10M sold.
Based on aggregated 13F filings for Q1 2026.